News and commentary from the psychiatry world
— News and commentary from the psychiatry world
July 15, 2026
• 2 min read
The FDA finalized clinical guidance for psychedelic drug developers and scheduled a public hearing for September to discuss potential therapeutic uses.
Meanwhile, HHS and the VA are partnering to speed up the research and development of rapid-acting psychedelic treatments for veterans with severe mental health conditions.
FDA finalizes guidance on psychedelics, plans broader hearing
VA, HHS Launch New Psychedelic Therapy Partnership That Will Impact More Than 1 Million Veterans
Americans for Ibogaine Welcomes Milestone as Federal Government Mobilizes Multiple Agencies to Advance Ibogaine Research and Psychedelic Medicine
FDA finalizes clinical guidance for psychedelic drugs, easing abuse-study requirements, and sets a Sept. 14 hearing on…
The FDA announced regulatory actions Friday to support development of serotonin-2A agonists and related products, including…
SAN FRANCISCO — Psychedelics in mental health treatment is a rapidly changing landscape, but it is important for primary care…
It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use…
In response to Trump's recent executive order, the FDA announced plans to expedite the review of certain psychedelic medicines…
Since President Donald J. Trump’s executive order to increase access to psychedelics and other alternative therapies for mental…
